7-methyl-2,3,4,9-tetrahydro-1H-carbazole | 21240-53-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-methyl-2,3,4,9-tetrahydro-1H-carbazole
• 英文别名: 7-methyl-1,2,3,4-tetrahydro-carbazole；7-Methyl-1,2,3,4-tetrahydro-carbazol；7-Methyl-1,2,3,4-tetrahydrocarbazol；7-Methyl-1,2,3,4-tetrahydrocarbazole
• CAS: 21240-53-9
• 化学式: C₁₃H₁₅N
• 分子量: 185.269
• InChiKey: SNFQRXLISIQTHH-UHFFFAOYSA-N

物化性质

• 熔点：
  134-137 °C
• 沸点：
  333.5±11.0 °C(Predicted)
• 密度：
  1.122±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  7-methyl-2,3,4,9-tetrahydro-1H-carbazole 在 palladium on activated charcoal 作用下， 以 various solvent(s) 为溶剂， 反应 5.5h， 以97%的产率得到2-甲基咔唑
  参考文献：
  名称：

  Kuroki, Masanate; Tsunashima, Yutaka, Journal of Heterocyclic Chemistry, 1981, vol. 18, p. 709 - 714

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(m-Tolyl)hydrazone of Cyclohexanone 生成 7-methyl-2,3,4,9-tetrahydro-1H-carbazole
  参考文献：
  名称：

  PRZHEVALSKIJ, N. M.;KOSTROMINA, L. YU.;GRANDBERG, I. I., XIMIYA GETEROTSIKL. SOED.,(1988) N 2, 188-192

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Sheth Urvi

  公开号：US20120309758A1

  公开（公告）日：2012-12-06

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• Ruthenium-Catalyzed Synthesis of Indoles from Anilines and Epoxides
  作者：Miguel Peña-López、Helfried Neumann、Matthias Beller

  DOI：10.1002/chem.201304432

  日期：2014.2.10

  A general synthetic route to indoles from readily available anilines and epoxides by using ruthenium catalysis is described. This straightforward transformation allows a variety of indoles to be obtained in good yields by using [Ru3(CO)12]/1,1′‐bis(diphenylphosphino)ferrocene as the catalytic system. Water and hydrogen are formed as the only stoichiometric by‐products, making this process highly atom

  描述了通过使用钌催化从易得的苯胺和环氧化物制备吲哚的一般合成途径。通过使用[Ru 3（CO）12 ] / 1,1'-双（二苯基膦基）二茂铁作为催化体系，这种简单的转化方法可以高收率获得各种吲哚。水和氢是唯一的化学计量副产物，因此该过程具有很高的原子效率。
• Modulators of ATP-Binding Cassette Transporters
  申请人：Hadida-Ruah Sara

  公开号：US20130035327A1

  公开（公告）日：2013-02-07

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜导电调节器，以及其组成物和使用这些调节剂的方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。